Skip to main content
. Author manuscript; available in PMC: 2008 Apr 30.
Published in final edited form as: Cell Immunol. 2007 Sep 7;247(1):36–48. doi: 10.1016/j.cellimm.2007.07.004

Table 1.

HLA-A2-peptide induced direct ex vivo IFN-γ ELISPOT responses of HLA-A2 positive healthy donors' PBMCa

Donors: #1 #2 #3 #4 #5 #6
HLA-A allele “a” 2-0201 2-0201 2-0201 2-0201 2-0201 2-0201
HLA-A allele “b” 33-3301 26-2601 2-0201 29-2902 24-2402 3-0301
HLA-A2-restricted peptides:
Flu Mat 158 (GILGFVFTL) 4 +/- 1 40+/- 12 72 +/- 38 28 +/- 4 33 +/- 1 4 +/- 0
Flu A (FMYSDFHFI) 24 +/- 10 37+/- 15 594 +/-142 32 +/- 6 32 +/- 3 6 +/- 0
EBV LMP2A (CLGGLLTMV) 139 +/- 15 3 +/- 1 779 +/-106 2 +/- 1 1 +/- 1 1 +/- 0
EBV BMLF1259 (GLCTLVAML) 13 +/- 1 12+/- 6 17 +/-3 7 +/- 1 4 +/- 1 35 +/- 11
HCMV pp65 495 (NLVPMVATV) 126 +/- 2 3 +/-1 762 +/-144 2 +/- 0 3 +/- 1 1 +/- 0
CEF peptide pool (32 peptides) 232 +/- 21 81 +/- 29 796 +/-60 273 +/-47 75 +/- 4 71 +/- 18
a

PBMC (2 × 105/ well) from the specified HLA-A2 positive donors (identified by high resolution typing) were cultured with the specified HLA-A2- or non-HLA-A2- restricted peptides (sequence specified, tested at 2 µg/ml) for 24 hr and the peptide-induced IFN-γ production was measured in a standard IFN-γ ELISPOT assay. CEF peptide pool (containing 32 peptides of EBV, CMV and flu) was also tested. In the negative control wells spot counts were smaller than 3 spots per well. The data are shown as mean IFN-γ SFU per 200,000 PBMC ± SD for triplicate wells for one experiment that has been reproduced twice with similar results – the inter-assay variation of peptide-induced responses was < 30%.